diet drugs – Page 4 – Diet Business Watch

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report

Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing […]

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over

News / John LaRosa

Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »

Conflicts in Trump Administration For Support of GLP-1 Meds

Uncategorized / John LaRosa

Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed

Conflicts in Trump Administration For Support of GLP-1 Meds Read More »

The Party Is Almost Over for GLP-1 Compounders

Uncategorized / John LaRosa

January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the

The Party Is Almost Over for GLP-1 Compounders Read More »

FDA Says Shortage Is Over, Compounders Have 60-90 Days

News / John LaRosa

Dec. 20, 2024 The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. Zepbound is FDA-approved to treat obesity and Mounjaro is approved for diabetes. They

FDA Says Shortage Is Over, Compounders Have 60-90 Days Read More »

Zepbound Beats Wegovy for Weight Loss

News / John LaRosa

Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists

Zepbound Beats Wegovy for Weight Loss Read More »

Weight Watchers Reports 3rd Quarter Results

News / John LaRosa

Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to

Weight Watchers Reports 3rd Quarter Results Read More »

Medifast Reports 3rd Quarter Results

News / John LaRosa

Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672

Medifast Reports 3rd Quarter Results Read More »

Invisible Medical Groups Are Behind GLP-1 Boom

News / John LaRosa

October 17, 2024 According to State Health, the telehealth GLP-1 boom wouldn’t be possible without clinicians willing to write prescriptions for those hundreds of thousands of patients. Companies are rarely transparent — with patients or the public — about the medical groups behind the screens. But a STAT examination found that just a handful of networks of

Invisible Medical Groups Are Behind GLP-1 Boom Read More »

Weight Watchers Adds Compounded Meds

News / John LaRosa

Oct. 8, 2024 WW announced the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions. The new offering, starting at $129, enhances the Company’s holistic weight management program, which includes behavioral and clinical solutions with support from board-certified clinicians, registered dietitians, and the global Weight Watchers community. This

Weight Watchers Adds Compounded Meds Read More »